Quantitative assessment of the cell penetrating properties of RI-Tat-9: evidence for a cell type-specific barrier at the plasma membrane of epithelial cells
- PMID: 15832511
- DOI: 10.1021/mp034014y
Quantitative assessment of the cell penetrating properties of RI-Tat-9: evidence for a cell type-specific barrier at the plasma membrane of epithelial cells
Abstract
Penetration of epithelial cells represents the rate-determining step for the absorption of many drugs and pharmaceutical macromolecules such as proteins and nucleic acid therapeutics. While the potential of using cell-penetrating peptides (CPPs) to facilitate absorption has been increasingly recognized, the mechanism of cell penetration and the uptake into certain cells have recently been called into question due to methodological artifacts. Therefore, the objective of this study was to quantitatively assess the ability of RI-Tat-9, a proteolytically stable CPP, to penetrate epithelial cell monolayers. The permeability of RI-Tat-9 with two epithelial cell lines, Madin-Darby canine kidney (MDCK) and Caco-2 cells, was comparable to the leakiness of the respective intact monolayers. Microscopic imaging showed that fluorescence-tagged RI-Tat-9 did not enter these cells, further supporting a paracellular transport mechanism. Although insufficient data were generated in these studies to generalize the observed phenomenon, the entry of RI-Tat-9 into nonepithelial T lymphocytic MT2 cells, possibly by endocytosis, suggested that a cell type-specific barrier might exist that controlled uptake of RI-Tat-9 by cells. Compared to that in MT2 and HeLa cells, the active uptake of the peptide into MDCK monolayers was much slower and showed no dependence of cell energy. Furthermore, the equilibrium binding of RI-Tat-9 to MDCK cells at 0 degrees C was indicative of an interaction with a nonspecific receptor. A correlation between binding density and concentration difference across a leaky separation barrier suggested that repulsion of free peptide molecules by bound peptide molecules at the MDCK monolayer surface may be significant at micromolar concentrations. The results of this study quantitatively show that Tat CPP uptake into two commonly used epithelial cell types is minimal and possibly cell type-specific. Implications for Tat CPP-assisted drug delivery are discussed.
Similar articles
-
Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide.Mol Pharm. 2009 May-Jun;6(3):836-48. doi: 10.1021/mp800121f. Mol Pharm. 2009. PMID: 19278221 Free PMC article.
-
Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate.Biochemistry. 2002 Oct 22;41(42):12652-61. doi: 10.1021/bi026097e. Biochemistry. 2002. PMID: 12379107
-
No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides.Biochim Biophys Acta. 2003 Jan 31;1609(2):161-9. doi: 10.1016/s0005-2736(02)00683-1. Biochim Biophys Acta. 2003. PMID: 12543377
-
TAT peptide internalization: seeking the mechanism of entry.Curr Protein Pept Sci. 2003 Apr;4(2):125-32. doi: 10.2174/1389203033487306. Curr Protein Pept Sci. 2003. PMID: 12678851 Review.
-
Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.Future Med Chem. 2011 Dec;3(16):2063-77. doi: 10.4155/fmc.11.149. Future Med Chem. 2011. PMID: 22098353 Review.
Cited by
-
Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide.Mol Pharm. 2009 May-Jun;6(3):836-48. doi: 10.1021/mp800121f. Mol Pharm. 2009. PMID: 19278221 Free PMC article.
-
Cell-penetrating peptides: achievements and challenges in application for cancer treatment.J Biomed Mater Res A. 2014 Feb;102(2):575-87. doi: 10.1002/jbm.a.34859. Epub 2013 Jul 30. J Biomed Mater Res A. 2014. PMID: 23852939 Free PMC article. Review.
-
Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS.Diseases. 2019 Jun 26;7(3):47. doi: 10.3390/diseases7030047. Diseases. 2019. PMID: 31248000 Free PMC article. Review.
-
Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.J Drug Deliv Sci Technol. 2009;19(1):3-14. doi: 10.1016/s1773-2247(09)50001-9. J Drug Deliv Sci Technol. 2009. PMID: 20717488 Free PMC article.
-
Functional chlorin gold nanorods enable to treat breast cancer by photothermal/photodynamic therapy.Int J Nanomedicine. 2018 Nov 29;13:8119-8135. doi: 10.2147/IJN.S186974. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30555230 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources